2023-07-16-世界卫生组织-Immunization_Uzbekistan_2023_country_profile_19页_367kb

Uzbekistan Immunization Coverage Summary (WHO & UNICEF, 2023)

🌍 Overall Performance:
The country demonstrates high, stable immunization coverage for key vaccines since the 2017-2018 period. Most vaccines maintain coverage above 95% for infants (born ~2 years before the survey/reporting window) across multiple indicators. The surveillance system shows robust coverage for routine childhood vaccines.

📊 Key Vaccines & Trends:

• BCG, DTP1/DTP3, Polio (Pol3), Measles (MCV1/MCV2), Hepatitis B (HepBB): Consistently high coverage (>95%) since 2017-2018, with minimal fluctuations.
• Hepatitis B (HepB3): Maintained above 95% coverage since 2017-2018.
• Inactivated Polio Vaccine (IPV1) & Oral Polio Vaccine (OPV):
  • IPV1 introduced nationally in 2018, achieved ~94% coverage in its target population two years post-introduction (2020-2021).
  • Routine OPV coverage remains consistently at ~99% (near universal) for younger infants born in/near years preceding 2018.
• Haemophilus influenzae type B (Hib3): Regularly above 95% coverage since 2017-2018.
• Rotavirus (RotaC) & Pneumococcal Conjugate Vaccine (PCV3): Still in early stages.
• Rubella Containing Vaccine (RCV1): Coverage estimates follow MCV1 closely (GoC=R+,S+,D+).

⚠️ Challenges & Caveats:

• Stockouts were probable in earlier years (pre-2017), but recent estimates (2017-2022) show minimal negative impact.
• All estimates carry some degree of uncertainty (GoC rating). Discrepancies noted between official, administrative, and survey-based (survey sparse and methods sometimes ad hoc) data.
• Coverage for newer vaccines typically has lower initial confidence ratings (GoC) due to incomplete data series.
• Some estimates (e.g., Rotavirus) are challenged by data sources/methodology, reflecting real-world gaps.

📅 Data: Last revision as of June 26, 2023. Next estimate update due July 15, 2024. Data available through linked WHO and UNICEF portals.

Conclusion:
Uzbekistan displays a mature immunization system with consistently high performance for its long-established schedules. While newer vaccines face initial adoption and data challenges, coverage appears robust going forward.